1. Home
  2. KNSA vs CENT Comparison

KNSA vs CENT Comparison

Compare KNSA & CENT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNSA
  • CENT
  • Stock Information
  • Founded
  • KNSA 2015
  • CENT 1955
  • Country
  • KNSA United Kingdom
  • CENT United States
  • Employees
  • KNSA N/A
  • CENT N/A
  • Industry
  • KNSA Biotechnology: Pharmaceutical Preparations
  • CENT Consumer Specialties
  • Sector
  • KNSA Health Care
  • CENT Consumer Discretionary
  • Exchange
  • KNSA Nasdaq
  • CENT Nasdaq
  • Market Cap
  • KNSA 2.1B
  • CENT 2.4B
  • IPO Year
  • KNSA 2018
  • CENT N/A
  • Fundamental
  • Price
  • KNSA $27.53
  • CENT $35.18
  • Analyst Decision
  • KNSA Strong Buy
  • CENT Strong Buy
  • Analyst Count
  • KNSA 5
  • CENT 2
  • Target Price
  • KNSA $38.80
  • CENT $42.50
  • AVG Volume (30 Days)
  • KNSA 1.1M
  • CENT 99.1K
  • Earning Date
  • KNSA 07-22-2025
  • CENT 08-06-2025
  • Dividend Yield
  • KNSA N/A
  • CENT N/A
  • EPS Growth
  • KNSA N/A
  • CENT N/A
  • EPS
  • KNSA N/A
  • CENT 1.87
  • Revenue
  • KNSA $481,166,000.00
  • CENT $3,155,810,000.00
  • Revenue This Year
  • KNSA $37.21
  • CENT $0.42
  • Revenue Next Year
  • KNSA $5.32
  • CENT $1.77
  • P/E Ratio
  • KNSA N/A
  • CENT $18.87
  • Revenue Growth
  • KNSA 59.45
  • CENT N/A
  • 52 Week Low
  • KNSA $17.38
  • CENT $31.97
  • 52 Week High
  • KNSA $30.69
  • CENT $43.88
  • Technical
  • Relative Strength Index (RSI)
  • KNSA 54.29
  • CENT 49.32
  • Support Level
  • KNSA $27.62
  • CENT $34.78
  • Resistance Level
  • KNSA $29.23
  • CENT $35.90
  • Average True Range (ATR)
  • KNSA 1.03
  • CENT 0.71
  • MACD
  • KNSA -0.21
  • CENT 0.03
  • Stochastic Oscillator
  • KNSA 46.99
  • CENT 40.88

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

About CENT Central Garden & Pet Company

Central Garden & Pet Co understands that home is central to life and has nurtured happy and healthy homes for over forty years. The segments of the company are the pet segment and garden segment. The company's trusted products are dedicated to helping lawns grow greener, gardens bloom bigger, pets live healthier and communities grow stronger. Central is home to a portfolio of more than sixty-five brands including Pennington, Nylabone, Kaytee, Amdro, and Aqueon, manufacturing and distribution capabilities, and a passionate, entrepreneurial growth culture. Central Garden and Pet is based in Walnut Creek, California, and has offices across North America and Europe.

Share on Social Networks: